Investigating how decorin and MRI can improve treatment for recurrent glioblastoma
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
This study is looking at how a special protein and MRI scans can help doctors figure out which patients with recurring glioblastoma might benefit the most from a treatment that blocks blood vessel growth in tumors, with the goal of improving outcomes for those patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11054702 on NIH RePORTER |
What this research studies
This research focuses on recurrent glioblastoma, a highly aggressive brain cancer with limited treatment options. It aims to explore the role of decorin and diffusion MRI in enhancing the effectiveness of bevacizumab, a drug that inhibits blood vessel growth in tumors. By identifying imaging biomarkers that predict which patients will benefit from this treatment, the study seeks to improve patient outcomes and guide future therapies. The approach involves analyzing MRI characteristics to stratify patients based on their likelihood of responding to anti-VEGF therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who are considering or currently receiving bevacizumab treatment.
Not a fit: Patients with glioblastoma who are not experiencing recurrence or those who are not eligible for bevacizumab may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with recurrent glioblastoma, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promising results using diffusion MRI as a predictive tool for treatment efficacy in glioblastoma, indicating that this approach has potential for success.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ellingson, Benjamin M. — University of California Los Angeles
- Study coordinator: Ellingson, Benjamin M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.